Regadenoson
Overview
Regadenoson is a selective A2A adenosine receptor agonist used as a pharmacologic stress agent for myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It is used clinically to help diagnose coronary artery disease via its ability to increase blood flow in the coronary vasculature.
API suppliers (11)
Suppliers of Regadenoson evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 7 of 11 suppliers.
4 of 11 hold a GMP certificate on record in the EU or UK registers
- BIOPHORE INDIA PHARMACEUTICALS PVT LTD1 active DMF
- CZECH-GEN AS1 active DMF
- NANJING HERON PHARMACEUTICAL CO LTD1 active DMF
- USV PRIVATE LTDIndia1 active DMF GMP on record
- GLAND PHARMA LTDIndia1 active DMF GMP on record
- SCINOPHARM TAIWAN LTDTaiwan1 active DMF
- CURIA MISSOURI INC1 active DMF
- Sun Pharmaceutical Industries LimitedIndia1 active DMF GMP on record
- MATRIX PHARMACORP PRIVATE LTDIndia1 active DMF
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
- FARMAK ASUkraine
Patent & exclusivity (US)
Per the FDA Orange Book (13 approved US products), the latest listed US patent on Regadenoson expires 2 Feb 2027. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Regadenoson? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.